Effectiveness of fluticasone propionate in patients with moderate asthma: a dose-ranging study (Q46965854)

26 December 2017

title

Effectiveness of fluticasone propionate in patients with moderate asthma: a dose-ranging study (English)

1 reference

26 December 2017

main subject

asthma

0 references

fluticasone propionate

1 reference

Wolfe JD

1

1 reference

26 December 2017

Selner JC

2

1 reference

26 December 2017

Mendelson LM

3

1 reference

26 December 2017

Hampel F Jr

4

1 reference

26 December 2017

Schaberg A

5

1 reference

26 December 2017

publication date

1 July 1996

1 reference

26 December 2017

published in

Clinical Therapeutics

1 reference

26 December 2017

volume

18

1 reference

26 December 2017

page(s)

635-646

1 reference

26 December 2017

issue

4

1 reference

26 December 2017

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980214-1

1 reference

7 January 2021

The human pharmacology of fluticasone propionate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980214-1

7 January 2021

Structure-activity relationships of topically active steroids: the selection of fluticasone propionate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980214-1

7 January 2021

Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. The Fluticasone Propionate Asthma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980214-1

7 January 2021

Standardization of spirometry--1987 update. Statement of the American Thoracic Society

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980214-1

7 January 2021

Aerosol beclomethasone dipropionate: a dose-response study in chronic bronchial asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980214-1

7 January 2021

Inhaled corticosteroids: benefits and risks

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980214-1

7 January 2021

Comparison of oral-steroid sparing by high-dose and low-dose inhaled steroid in maintenance treatment of severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980214-1

7 January 2021

A 12-week dose-ranging study of fluticasone propionate powder in the treatment of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980214-1

7 January 2021

Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980214-1

7 January 2021

A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. International Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980214-1

7 January 2021

Evaluation of fluticasone propionate (500 micrograms day-1) administered either as dry powder via a Diskhaler inhaler or pressurized inhaler and compared with beclomethasone dipropionate (1000 micrograms day-1) administered by pressurized inhaler

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980214-1

7 January 2021

Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. International Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980214-1

7 January 2021

A comparison of fluticasone propionate 200 micrograms/day with beclomethasone dipropionate 400 micrograms/day in adult asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980214-1

7 January 2021

10.1016/S0149-2918(96)80214-1

Identifiers

DOI

1 reference

26 December 2017

PubMed ID

8879892

1 reference

26 December 2017